Drug Profile
Nivolumab subcutaneous administration - Revolka
Alternative Names: RK-001Latest Information Update: 05 Jul 2023
Price :
$50
*
At a glance
- Originator RevolKa
- Class Antineoplastics; Antivirals; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer